Go Deep
COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,259 | -1.5 | 0.41 | 0.13 | 576.29 |
COSCIENS Biopharma Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 3,143,000.0 | 1,888,000.0 | 1,766,000.0 | 1,483,000.0 |
| Net Profit | -202,000.0 | 10,757,000.0 | -2,183,000.0 | -1,819,000.0 |
| EPS | -0.2 | 10.3 | — | -1.7 |
COSCIENS Biopharma Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 7,498,000.0 | 9,587,000.0 | 7,143,000.0 | 14,572,000.0 | — |
| Net Profit | -10,358,000.0 | -15,309,000.0 | -3,485,000.0 | 3,448,000.0 | — |
| EPS | -9.8 | -17.8 | -5.7 | 5.6 | — |
COSCIENS Biopharma Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 21,431,000.0 | 35,070,000.0 | 23,745,000.0 | 27,803,176.4 | — |
| Total Liabilities | 17,589,000.0 | 21,909,000.0 | 2,710,000.0 | 4,012,217.8 | — |
| Total Equity | 3,842,000.0 | 13,161,000.0 | 21,035,000.0 | 23,790,958.6 | — |
COSCIENS Biopharma Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 34.1%Receivables 5.9%Inventory 6.1%Fixed assets (tangible) 45.8%Other assets 8.2%
How it's funded — Dec 2025
Short-term debt 1.0%Long-term debt 9.0%Payables 3.5%Other liabilities 68.6%Shareholders' equity 17.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 7.3 | 16.4 | 6.7 | 10.2 |
| Receivables | 1.3 | 2.5 | 0.3 | 2.1 |
| Inventory | 1.3 | 2.7 | 4.0 | 2.8 |
| Fixed assets (tangible) | 9.8 | 11.0 | 11.6 | 11.9 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.8 | 2.5 | 1.1 | 0.8 |
| Liabilities & equity | ||||
| Short-term debt | 0.2 | 0.3 | 0.3 | 0.3 |
| Long-term debt | 1.9 | 2.0 | 1.4 | 1.7 |
| Payables | 0.7 | 2.4 | 0.3 | 1.3 |
| Other liabilities | 14.7 | 17.2 | 0.7 | 0.8 |
| Shareholders' equity | 3.8 | 13.2 | 21.0 | 23.8 |
| Net tangible assets | 3.8 | 13.2 | 21.0 | 23.8 |
COSCIENS Biopharma Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -8,473,000.0 | -14,568,000.0 | -2,582,000.0 | 5,229,000.0 | — |
| Investing Activities | -458,000.0 | 25,083,000.0 | -730,000.0 | -304,000.0 | — |
| Financing Activities | -407,000.0 | -588,000.0 | -357,000.0 | -267,000.0 | — |